- Home
- SUGP vs SNSE Comparison
SUGP vs SNSE Comparison
Compare SUGP & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUGP
- SNSE
- Stock Information
- Founded
- SUGP 1998
- SNSE 2005
- Country
- SUGP Hong Kong
- SNSE United States
- Employees
- SUGP N/A
- SNSE N/A
- Industry
- SUGP
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- SUGP
- SNSE Health Care
- Exchange
- SUGP NYSE
- SNSE Nasdaq
- Market Cap
- SUGP 8.9M
- SNSE 9.3M
- IPO Year
- SUGP 2024
- SNSE 2021
- Fundamental
- Price
- SUGP $0.80
- SNSE $0.34
- Analyst Decision
- SUGP
- SNSE Strong Buy
- Analyst Count
- SUGP 0
- SNSE 4
- Target Price
- SUGP N/A
- SNSE $4.25
- AVG Volume (30 Days)
- SUGP 30.6K
- SNSE 150.3K
- Earning Date
- SUGP 07-21-2025
- SNSE 05-06-2025
- Dividend Yield
- SUGP N/A
- SNSE N/A
- EPS Growth
- SUGP 1.19
- SNSE N/A
- EPS
- SUGP 0.11
- SNSE N/A
- Revenue
- SUGP $23,446,259.00
- SNSE N/A
- Revenue This Year
- SUGP N/A
- SNSE N/A
- Revenue Next Year
- SUGP N/A
- SNSE N/A
- P/E Ratio
- SUGP $7.62
- SNSE N/A
- Revenue Growth
- SUGP 11.29
- SNSE N/A
- 52 Week Low
- SUGP $0.52
- SNSE $0.25
- 52 Week High
- SUGP $3.25
- SNSE $0.87
- Technical
- Relative Strength Index (RSI)
- SUGP 49.03
- SNSE 50.22
- Support Level
- SUGP $0.76
- SNSE $0.31
- Resistance Level
- SUGP $0.86
- SNSE $0.33
- Average True Range (ATR)
- SUGP 0.08
- SNSE 0.04
- MACD
- SUGP -0.02
- SNSE 0.01
- Stochastic Oscillator
- SUGP 14.71
- SNSE 75.25
About SUGP SU GROUP HLDGS LTD
SU Group Holdings Ltd and its subsidiaries is an integrated security-related services company. The company has two reportable segments: security-related engineering services, and security guarding and screening services and related vocational training services. The company generates the majority of its revenue from the security-related engineering services segment. Geographically operates in Hong Kong, and Other foreign countries, with maximum revenue from Kong Kong.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).